Substance / Medication

Orlistat

Overview

Active Ingredient
orlistat
RxNorm CUI
37925

Indications

2 2 XENICAL is indicated for obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet. XENICAL is also indicated to reduce the risk for weight regain after prior weight loss. XENICAL is indicated for obese patients with an initial body mass index (BMI) ≥30 kg/mor ≥27 kg/min the presence of other risk factors (e.g., hypertension, diabetes, dyslipidemia). Table 1 ' " illustrates body mass index (BMI) according to a variety of weights and

Labeler: H2-Pharma LLCUpdated: 2024-07-08T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

XENICAL is contraindicated in: Use in Specific Populations (8.1) [see] Pregnancy Patients with chronic malabsorption syndrome Patients with cholestasis Patients with known hypersensitivity to XENICAL or to any component of this product

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

426 trials linked to this intervention

426
Total Trials
122
Recruiting
109
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Effects of orlistat on body mass index and serum lipids in overweight and obese adolescents: a meta-analysis.
Zhang Lingnan, Meng Chang, Zhang Fang et al. · J Pediatr Endocrinol Metab · 2025
PMID: 39648190Meta-Analysis
Efficacy and safety of orlistat in controlling the progression of prediabetes to diabetes: A meta-analysis and systematic review.
Gao Zhao, Huang Mengwen, Wang Jiaxin et al. · Medicine (Baltimore) · 2024
PMID: 38787971Meta-AnalysisFull text (PMC)
Effect of Orlistat on anthropometrics and metabolic indices in children and adolescents: a systematic review and meta-analysis.
Nikniaz Zeinab, Nikniaz Leila, Farhangi Mahdieh Abbasalizad et al. · BMC Endocr Disord · 2023
PMID: 37420181Meta-AnalysisFull text (PMC)
Effects of oral contraceptives plus orlistat in patients with polycystic ovary syndrome and overweight/obesity: A meta-analysis.
Chen Zhangming, Cai Zhaowei · J Obstet Gynaecol Res · 2022
PMID: 35302695Meta-Analysis
Effect of orlistat on serum uric acid level in adults: A systematic review and meta-analysis of randomised controlled trials.
Noori Soheila, Mirzababaei Atieh, Amini Mohammad Reza et al. · Int J Clin Pract · 2021
PMID: 34324762Meta-Analysis
Effects of orlistat on blood pressure: a systematic review and meta-analysis of 27 randomized controlled clinical trials.
Sahebkar Amirhossein, Simental-Mendía Luis E, Kovanen Petri T et al. · J Am Soc Hypertens · 2018
PMID: 29275922Meta-Analysis
Bariatric surgery, lifestyle interventions and orlistat for severe obesity: the REBALANCE mixed-methods systematic review and economic evaluation.
Avenell Alison, Robertson Clare, Skea Zoë et al. · Health Technol Assess · 2018
PMID: 30511918Meta-AnalysisFull text (PMC)
Effect of orlistat on plasma lipids and body weight: A systematic review and meta-analysis of 33 randomized controlled trials.
Sahebkar Amirhossein, Simental-Mendía Luis E, Reiner Željko et al. · Pharmacol Res · 2017
PMID: 28559211Meta-Analysis
Improvement of plasma adiponectin, leptin and C-reactive protein concentrations by orlistat: a systematic review and meta-analysis.
Derosa Giuseppe, Maffioli Pamela, Sahebkar Amirhossein · Br J Clin Pharmacol · 2016
PMID: 26717446Meta-AnalysisFull text (PMC)
Reporting of harms outcomes: a comparison of journal publications with unpublished clinical study reports of orlistat trials.
Hodkinson Alex, Gamble Carrol, Smith Catrin Tudur · Trials · 2016
PMID: 27103582Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Orlistat (substance)
SNOMED CT
387007000
UMLS CUI
C0076275
RxNorm CUI
37925
Labeler
H2-Pharma LLC

Clinical Data

This intervention maps to 9 entities in the Ltrl knowledge graph.

1
Conditions
3
Biomarkers
3
Specialists
0
Symptoms
426
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.